Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
Open Access
- 18 September 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9), 3022
- https://doi.org/10.3390/jcm9093022
Abstract
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is universally expressed by normal and neoplastic plasma cells and plays a critical role in the proliferation, survival and tumor progression in multiple myeloma (MM). B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have been recognized as proliferation ligands for BCMA in the bone marrow microenvironment. Soluble BCMA levels in the serum correlates with disease phase and tumor burden and is a predictor of progression-free survival (PFS) and overall survival (OS). Recently, the introduction of new monoclonal antibodies against CD38 (Daratumumab and Isatuximab) and SLAM7 (Elotuzumab) has changed the therapeutic approach to MM, improving the response rate and the time to progression, both in newly diagnosed and refractory/relapsed patients. Among the surface antigens on MM cells, BCMA is a suitable target for the design of new antibody-based strategies. Experimental approaches targeting BCMA are currently being investigated and include antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and genetically engineered T-cells with chimeric antigen receptors (CAR). In this review we summarize the more recent findings about BCMA biologic rationale as a therapeutic target and report the updated results of preclinical and clinical studies focused on ADCs and bsAbs targeting BCMA.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG2017 n. 20299)
This publication has 52 references indexed in Scilit:
- APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loopEuropean Journal of Haematology, 2009
- B‐Lymphocyte stimulator: a new biomarker for multiple myelomaEuropean Journal of Haematology, 2009
- Antibody targeting of B-cell maturation antigen on malignant plasma cellsMolecular Cancer Therapeutics, 2007
- Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRILBlood, 2006
- The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureBlood, 2005
- Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptorBlood, 2005
- BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneBlood, 2004
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004
- BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma CellsThe Journal of Experimental Medicine, 2004
- BAFF and APRIL: A Tutorial on B Cell SurvivalAnnual Review of Immunology, 2003